Price movement over the last 24 hours
Global X Artificial Intelligence & Technology ETF vs Danaher Corporation — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $62.57, while Danaher Corporation trades at $190.62 (market cap $137.44B). The key difference: Danaher Corporation pays a 0.82% dividend while Global X Artificial Intelligence & Technology ETF pays none, and Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, Danaher Corporation nearer its low. Which is the better fit depends on your goals.
| AIQ | DHR | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $242.05 |
52-Week Low | $43.28 | $161.91 |
Market Cap | — | $137.44B |
Enterprise Value | — | $150.22B |
Dividend Yield | — | 0.82% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Danaher (DHR) trades at $190.77, down 1.47% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company maintains solid fundamentals with consistent earnings beats, a 14.89% net income margin, and positive cash flow of $2.54B in 2025. Recent developments include the Masimo acquisition approval and new product launches in the biotechnology segment.
The stock presents a compelling opportunity with 69% analyst buy ratings and a $214.73 price target suggesting 12.6% upside. Key risks include revenue stagnation from $24.6B in 2025 to projected $24.8B in 2026 and the recent $172.5M legal settlement over pandemic-era disclosures. Biotechnology segment growth at 7% remains a positive catalyst.
Trailing returns across standard periods
Latest headlines on both assets
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →